AXSM
Axsome Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$155.81
−0.85%Oct 7, 2026, 11:00 UTC
Axsome Therapeutics announced that it will report its third-quarter 2026 financial results on November 2, 2026, before U.S. markets open, followed by a management conference call at 8:00 a.m. Eastern Time.
Source:Sep 28, 2026, 20:17 UTC
Tempest Therapeutics, Inc. appointed Constance Ames as Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary, effective September 22, 2026.
Sep 21, 2026, 11:00 UTC
Axsome Therapeutics announced results of the Shared Goals: Navigating Alzheimer's Agitation survey at Psych Congress 2026 in New Orleans in connection with World Alzheimer's Day.
Source:Sep 17, 2026, 11:00 UTC
Axsome Therapeutics presented ten posters, including new data in major depressive disorder and Alzheimer's disease agitation, at Psych Congress 2026 in New Orleans on September 17, 2026.
Source:Sep 1, 2026, 17:05 UTC
Axsome Therapeutics began dosing in the Phase III SUMMIT study of AXS-05 for smoking cessation in adults.
Source:Aug 23, 2026, 08:03 UTC
BlackRock Inc. acquired a new minority stake in Axsome Therapeutics, Inc., buying 3,103,708 shares valued at approximately $759.70 million during the second quarter, as disclosed in its 13F filing with the SEC.
Source:Aug 10, 2026, 11:00 UTC
Axsome Therapeutics initiated FOCUS-2 and FOCUS-3 Phase 3 trials of solriamfetol in children and adolescents with ADHD.
Source:Aug 10, 2026, 11:00 UTC
Axsome Therapeutics reported second quarter 2026 financial results with total net product revenue of $218.4 million, a 46% year-over-year increase.
Aug 10, 2026, 08:54 UTC
Axsome Therapeutics CEO Herriot Tabuteau sold 4,660 shares of the company's stock on August 6, 2026, at an average price of $213.95, totaling $997,007.
Source:Jul 16, 2026, 17:01 UTC
The FDA accepted Axsome Therapeutics' New Drug Application for AXS-12 for the treatment of cataplexy in narcolepsy and set a decision date of May 2027.
Source:Jul 7, 2026, 11:00 UTC
Axsome Therapeutics dosed the first patient in the FOCUS-2 Phase 3 trial of solriamfetol for children with ADHD.
Source:Jun 6, 2026, 04:02 UTC
Axsome Therapeutics is preparing to launch Auvelity for Alzheimer's disease agitation this month.
Source:Jun 3, 2026, 11:00 UTC
Axsome Therapeutics resolved all patent litigation related to its product SUNOSI (solriamfetol).
Source: